Brokerage firm Motilal Oswal has maintained a 'Buy' rating on Star Health and Allied Insurance with a target price of ₹700, citing improved underwriting and premium growth. While the company is benefiting from a strong retail health market share, investors should monitor rising competition and regulatory sensitivity regarding pricing and claim settlements.
What The Brokerage Said
Brokerage firm Motilal Oswal has reiterated its 'Buy' stance on Star Health and Allied Insurance (STARHEAL). The firm has set a target price of ₹700 per share, based on its valuation of the company's expected profit after tax for FY28. This view highlights the company's established position in the Indian retail health insurance market.
The Retail Health Growth Story
Star Health’s growth is closely tied to the broader retail health insurance sector in India. This segment has been expanding rapidly, with estimates suggesting a compound annual growth rate of approximately 18% between FY20 and FY25. Several factors support this, including rising healthcare costs, greater public awareness, and the move toward more private insurance penetration among the middle class. Star Health has maintained a significant market share of over 30% in this specific category since FY21, which allows it to benefit directly from this sector-wide expansion.
Financial Performance And Loss Ratios
For an insurance company, the 'loss ratio' is a key metric—it represents the portion of premium income paid out to cover claims. A lower ratio generally indicates better profitability. Star Health has shown recovery in this area, with its retail loss ratio improving to 68.2% in FY26, compared to 69.2% in FY25. The company’s ability to manage this ratio is driven by its strategy of repricing products and maintaining a strong growth in new business, which grew by 37% year-on-year in FY26. Managing these ratios effectively is critical for the company to sustain its margins amidst the underwriting business.
Business Risks And Competitive Pressure
While the brokerage report is positive, investors should be aware of the inherent risks in the health insurance business. First, the sector is seeing intense competition from large, multi-line insurance players who have deeper pockets and wider distribution networks. This competition can put pressure on premium pricing and market share. Second, the insurance industry is highly sensitive to regulatory oversight. Changes in guidelines by the Insurance Regulatory and Development Authority of India (IRDAI) regarding pricing models, claim settlement timelines, or product structures can directly impact the company's operational flexibility and profit margins.
What Investors Should Track
Investors may want to watch several factors that could influence the company’s future performance. The first is the trend in loss ratios; any significant spike in claims could hurt profitability. Second, it will be important to observe how the company balances its repricing initiatives with the need to acquire new customers in a competitive market. Finally, any updates from the regulator regarding health insurance norms could alter the business landscape, making management commentary in future earnings calls a key monitorable for shareholders.